NCPE withholds reimbursement support for first-line amivantamab regimen pending stronger cost effectiveness

NCPE completed its full assessment on 10 March 2026 and recommended against reimbursement of amivantamab with carboplatin and pemetrexed for first-line EGFR exon 20 insertion NSCLC unless cost effectiveness improves.